Last updated on January 2017

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)


Brief description of study

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA for treatment of seizures in patients with epilepsy. In this study, perampanel will be used off-label for adults with ALS at an oral medication dose on the low end of the recommended dose range for epilepsy. This study will consist of two treatments arms: perampanel and matching placebo randomized at a 1:1 ratio. Subjects will receive medication for 9 months.

Clinical Study Identifier: NCT03020797

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Diana Kaell, BA

Stony Brook University Medical Center
Stony Brook, NY United States
  Connect »